- March 29, 2022
- 12:30 PM - 3:00 PM ET
Attend the workshop:
The U.S. Food and Drug Administration (FDA), in partnership with the Reagan-Udall Foundation for the FDA, will hold a virtual public meeting entitled "Naloxone Access: Answering Questions."
Drug overdose persists as a major public health issue in the United States, killing 100,000 people from May 2020-April 2021. That’s the highest recorded number of overdose deaths in a 12-month period in the US according to the Centers for Disease Control and Prevention. Synthetic opioids, such as fentanyl, were the primary driver of the increase in overdose deaths.
This virtual public meeting will explore some of the most frequently asked questions about access to naloxone, a drug used to reverse opioid overdoses. Stakeholders to include harm reduction specialists, physicians, pharmacists, and regulators will be able to share their experiences in addressing the availability of this life-saving medication for heroin, fentanyl, and prescription opioid overdose.